**Medications for Substance Use Disorders Special Interest Group Meeting Minutes**

**Wednesday, November 3, 2021**

Chair: Emily Loscalzo, PsyD – eloscalzo@fight.org

* Introductions
	+ Name, specialty, setting(s) worked in, interest in meds for SUDS
	+ All new attendees to this SIG
* Discussion
	+ Question about experiences with meds for stimulant use disorder
		- Since outcomes with purported meds are equivocal at best, consider contingency management instead
			* Not MSUD but should be standard practice since provides best outcomes
			* Problem is that federal law will not allow patients in treatment to be paid anything greater than $75 by provider
				+ Advocacy in California to override this, but did not go through
			* Technical assistance is available for contingency management in OBOTs
			* Bryan Hartzler was identified as a good resource for contingency management
			* RESET- app that has contingency management built in
				+ Spin wheel, get gift cards
				+ One app for stimulant use disorder and another for other SUDs
			* DEI Issues: access to technology, response of different races to contingency management, ensuring non-coercion, considering doing away with gift cards for people with SUD as they perpetuate stigma (using cash instead)
		- No good anecdotal data re: bupropion/naltrexone for methamphetamine use disorder
			* Major barrier: IM naltrexone is denied by insurance for this purpose, only approved for AUD or OUD
			* Data are also not very compelling in NEJM study
			* Mixed results with bupropion alone
	+ Methadone
		- Changes in regs due to COVID- remain in place but at risk of returning to the past restrictive regs
		- Much advocacy needed in this area
* Next steps
	+ Join AMERSA Advocacy Committee
	+ Attend upcoming ASAM Advocacy Summit (next Wednesday 11/10/21, 4pm-6:30pm)
	+ Continue advocacy efforts throughout the year in areas of contingency management and methadone regs
	+ Consider putting out position statement
	+ Email addresses were provided for follow up